- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03598426
Conventional Prophylactic Oral Dexamethasone vs Short-course IV Dexamethasone in Paclitaxel Hypersensitivity
Conventional Prophylactic Regimen of Oral Dexamethasone Versus Short-course Intravenous Dexamethasone in Preventing Paclitaxel-related Hypersensitivity Reactions in Breast and Gynecologic Oncology Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Kofi Donkor, PharmD
- Phone Number: 15039 909-558-4000
- Email: kndonkor@llu.edu
Study Contact Backup
- Name: Linda Hong, MD
- Phone Number: 15504 909-558-4000
- Email: lihong@llu.edu
Study Locations
-
-
California
-
Loma Linda, California, United States, 92354
- Recruiting
- Loma Linda University Cancer Center
-
Contact:
- Kofi Donkor, PharmD
- Phone Number: 15039 909-558-4000
- Email: kndonkor@llu.edu
-
Contact:
- Linda Hong, MD
- Phone Number: 15504 909-558-4000
- Email: lihong@llu.edu
-
Sub-Investigator:
- Julie Selim, PharmD
-
Sub-Investigator:
- Yevgeniya Ioffe, MD
-
Sub-Investigator:
- Mazdak Momeni, MD
-
Sub-Investigator:
- Kofi Donkor, PharmD
-
Sub-Investigator:
- Gayathri Nagaraj, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adult female patients > 18 years of age
- Patients of the Loma Linda University Health (LLUH) gynecologic oncology and breast oncology service
- Confirmed breast or gynecologic cancer diagnosis of any stage and any gynecologic or breast malignancy
- Planned treatment with paclitaxel containing regimen either in the adjuvant setting or for palliation
- Planned treatment with paclitaxel should be for 3 or more cycles given as a weekly or every 3 weeks cycle
Paclitaxel should be given as a monotherapy or as part of a combination regimen. If paclitaxel is part of a regimen containing other drugs, the following conditions must be met:
- Paclitaxel will be the first chemotherapy regimen to be infused when patient comes in for treatment
- Chemotherapy regimen that would be approved for the study are the following:
i. Paclitaxel/ Carboplatin ii. Paclitaxel/Carboplatin/Bevacizumab iii. Paclitaxel/Cisplatin/Bevacizumab iv. Paclitaxel/Bevacizumab v. Paclitaxel/ Ifosfamide vi. Paclitaxel/ Pazopanib
- Patients should have no prior exposure to taxanes (this includes: paclitaxel, docetaxel, and protein-bound paclitaxel)
- The chemotherapy treatment should be at one of the LLUH Adult Cancer Centers
- The patient should be an English or Spanish speaking patient
Exclusion Criteria:
- Patients who are not with the gynecologic or breast oncology service
- Patients who are with the gynecologic oncology or breast oncology service but are not receiving paclitaxel either as a monotherapy or in combination with other regimen
- Patients who have had prior exposure to taxanes (this includes: paclitaxel, docetaxel, and protein-bound paclitaxel)
- Patients who are currently on steroid therapy and it is anticipated that therapy will not be discontinued at least a week prior to start of chemotherapy
Patients with autoimmune diseases, malignancies, and any other co-morbid condition that might require steroid therapy during chemotherapy. This includes, but not limited to:
- Crohn's disease
- Immune thrombocytopenia
- Lupus nephritis
- Multiple sclerosis
- Primary brain tumors
- Multiple Myeloma
- Hodgkin's Lymphoma
- Patients with uncontrolled diabetes or diabetic or pre-diabetic patients with baseline A1C levels > 8.5
- Patients who are allergic to diphenhydramine and/or dexamethasone
- Non-English and Non-Spanish speaking patients
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Conventional
Oral dexamethasone (20 mg) at home, 12 hours and 6 hours prior to paclitaxel infusion.
On the day of treatment at the clinic, an intravenous administration of diphenhydramine 50 mg and famotidine 20 mg, administered 30 minutes prior to paclitaxel infusion.
|
Conventional arm will only use oral dexamethasone as intervention; Short-Course arm will only use intravenous dexamethasone as intervention; Combined arm will use both oral and intravenous dexamethasone as intervention
Other Names:
|
Active Comparator: Short-Course
Intravenous administration of dexamethasone 20 mg, along with an intravenous administration of diphenhydramine 50 mg and famotidine 20 mg, administered 30 minutes prior to paclitaxel infusion.
|
Conventional arm will only use oral dexamethasone as intervention; Short-Course arm will only use intravenous dexamethasone as intervention; Combined arm will use both oral and intravenous dexamethasone as intervention
Other Names:
|
Active Comparator: Combined
Oral dexamethasone (20 mg) at home, 12 hours prior to paclitaxel infusion.
On the day of treatment at the clinic, an additional intravenous administration of dexamethasone 20 mg, along with an intravenous administration of diphenhydramine 50 mg and famotidine 20 mg, administered 30 minutes prior to paclitaxel infusion.
|
Conventional arm will only use oral dexamethasone as intervention; Short-Course arm will only use intravenous dexamethasone as intervention; Combined arm will use both oral and intravenous dexamethasone as intervention
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Least incidence of any-grade-paclitaxel-HSR first cycle
Time Frame: 1 to 3 HOURS
|
The treatment group that had the least incidence of any-grade-paclitaxel-HSR in the first cycle of chemotherapy treatment
|
1 to 3 HOURS
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Least incidence of any-grade-paclitaxel-HSR in the first and second cycles
Time Frame: 1 to 3 HOURS
|
The treatment group that had the least incidence of any-grade-paclitaxel-HSR in the first and second cycles of chemotherapy treatment
|
1 to 3 HOURS
|
Least incidence of grade 3 or more paclitaxel-HSR in the first and second cycles
Time Frame: 1 to 3 HOURS
|
The treatment group that had the least incidence of grade 3 or more paclitaxel-HSR in the first and second cycles of chemotherapy treatment
|
1 to 3 HOURS
|
Least incidence of any-grade-paclitaxel-HSR second cycle
Time Frame: 1 to 3 HOURS
|
The treatment group that had the least incidence of any-grade-paclitaxel-HSR in the second cycle of chemotherapy treatment
|
1 to 3 HOURS
|
Least incidence of grade 3 or more paclitaxel-HSR first cycle
Time Frame: 1 to 3 HOURS
|
The treatment group that had the least incidence of grade 3 or more paclitaxel-HSR in the first cycle of chemotherapy treatment
|
1 to 3 HOURS
|
Least incidence of grade 3 or more paclitaxel-HSR second cycle
Time Frame: 1 to 3 HOURS
|
The treatment group that had the least incidence of grade 3 or more paclitaxel-HSR in the second cycle of chemotherapy treatment
|
1 to 3 HOURS
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Linda Hong, MD, Loma Linda University Cancer Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Hypersensitivity
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Dexamethasone
Other Study ID Numbers
- 5180198
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypersensitivity Reactions
-
Centre hospitalier de l'Université de Montréal...CompletedPrevention of Hypersensitivity Reactions to PaclitaxelCanada
-
Zhong WangRecruitingAdverse Drug Event | Adverse Drug Reactions | Severe Adverse Reactions | Anaphylactic ReactionChina
-
Saglik Bilimleri UniversitesiCompletedAdverse Drug ReactionsTurkey
-
Chang Gung Memorial HospitalNational Science Council, TaiwanCompletedDrug HypersensitivityTaiwan
-
University Hospital, GrenobleTerminatedAllergic Hypersensitivity Drug Reaction Versus Non-allergic Hypersensitivity Drug Reaction Cross ReactionFrance
-
PharmAthene, Inc.National Institute of Allergy and Infectious Diseases (NIAID); National Institutes...CompletedAllergic ReactionsUnited States
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedAllergic Reactions
-
Suodi ZHAIPeking University; The Second Hospital of Hebei Medical University; West China... and other collaboratorsCompletedAdverse Drug Reaction | Drug AllergyChina
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedAllergic Reactions
-
University Hospital, Strasbourg, FranceRecruitingHypersensitivity, DrugFrance
Clinical Trials on Dexamethasone
-
Ottawa Hospital Research InstituteCompletedPain Syndrome | Early-stage Breast CancerCanada
-
Centre hospitalier de l'Université de Montréal...CompletedPrevention of Hypersensitivity Reactions to PaclitaxelCanada
-
Universidade Federal de PernambucoCompletedDiabetic Macular EdemaBrazil
-
Shanghai Jiao Tong University Affiliated Sixth...CompletedAnalgesia | Time | Brachial Plexus Block | Shoulder Surgery | Dexamethasone | Intravenous Drug UsageChina
-
Vanderbilt University Medical CenterTerminatedAsthma | CroupUnited States
-
Dr. Stephen ChoiThe Physicians' Services Incorporated FoundationCompletedShoulder Surgery | Nerve BlockCanada
-
Universitätsklinikum Hamburg-EppendorfGemeinsamer Bundesausschuss (G-BA); Staburo GmbHRecruiting
-
Poznan University of Medical SciencesRecruitingWrist Injuries | Hand Injuries | Hand Injuries and Disorders | Hand Disease | Wrist DiseasePoland
-
University of California, San FranciscoCompletedOral Lichen Planus | Pemphigus Vulgaris | Mucous Membrane Pemphigoid | Chronic Graft-versus-host-diseaseUnited States
-
University of BelgradeCompleted